Sector News

Agfa Gevaert says Kanteron Systems takeover offer "not interesting"

September 17, 2018
Life sciences

Shares in digital imaging systems producer Agfa Gevaert climbed on Thursday after it said it had declined to engage in talks with privately-held Kanteron Systems regarding a potential takeover bid.

The company said that it had received a non-binding letter of intent from Kanteron Systems relating to a voluntary conditional leveraged takeover offer on Sept. 11, confirming information from a blog post published by Kanteron a day before.

“Agfa Healthcare business unit revenues have been stagnant in the last few years. However, a deal with Kanteron would allow Agfa to tap into our leading-edge technology,” Kanteron Systems CEO Jorge Cortellin said in the post.

Kanteron Systems is a Spanish software company active in the healthcare and biomedical IT business, helping manage imaging and genomics data for precision medicine applications.

Agfa said in a statement that its management decided not to engage in discussions with Kanteron Systems at this stage.

Contacted for further comment, company spokesman Johan Jacobs said that “at this stage, we are not convinced that it’s an interesting offer”.

Kanteron Systems was not immediately available for comment.

Agfa’s shares jumped 8.5 percent on the Brussels stock exchange, right after the announcement. At 0840 GMT, the shares were up 3.6 percent.

By Piotr Lipinski

Source: Reuters

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).